Experienced in Primary Immunodeficiency (PID)

Dr. Donald E. Goodin

Hematology Oncology | Hematology | Oncology
Baptist Health Medical Group Inc
521 Robinbrooke Blvd, 
Elizabethtown, KY 
Clinical Trials:Currently Recruiting for 2 Trials
Accepting New Patients
Experienced in Primary Immunodeficiency (PID)
Baptist Health Medical Group Inc
521 Robinbrooke Blvd, 
Elizabethtown, KY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Donald Goodin is a Hematologist Oncology specialist and a Hematologist in Elizabethtown, Kentucky. Dr. Goodin is rated as an Experienced provider by MediFind in the treatment of Primary Immunodeficiency (PID). His top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), Lung Adenocarcinoma, and Lung Cancer. Dr. Goodin is currently accepting new patients.

His clinical research consists of co-authoring 1 peer reviewed article and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in KY
Hospital Affiliations
T J Samson Community Hospital
Owensboro Health Twin Lakes Medical Center
Baptist Health Hardin
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

BAPTIST HEALTH MEDICAL GROUP INC
521 Robinbrooke Blvd, Elizabethtown, KY 42701

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

LUNGMAP: A Master Protocol To Evaluate Biomarker-Driven Therapies And Immunotherapies In Previously-Treated Non-Small Cell Lung Cancer (Lung-Map Screening Study)
LUNGMAP: A Master Protocol To Evaluate Biomarker-Driven Therapies And Immunotherapies In Previously-Treated Non-Small Cell Lung Cancer (Lung-Map Screening Study)
Enrollment Status: Recruiting
Publish Date: March 13, 2025
Intervention Type: Drug
Study Drug: Screening Platform
Study Phase: Phase 2/Phase 3
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Enrollment Status: Recruiting
Publish Date: July 03, 2024
Intervention Type: Other, Drug
Study Drug: Crizotinib
Study Phase: Phase 3
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: October 06, 2025
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Drug
Study Drug: Erlotinib Hydrochloride
Study Phase: Phase 3
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled Pilot Study of an Oral, Selective Peripheral Opioid Receptor Antagonist in Advanced Non-Small Cell Lung Cancer
A Randomized, Double-Blind, Placebo-Controlled Pilot Study of an Oral, Selective Peripheral Opioid Receptor Antagonist in Advanced Non-Small Cell Lung Cancer
Enrollment Status: Terminated
Publish Date: July 17, 2025
Intervention Type: Other, Drug
Study Drug: Naloxegol
Study Phase: Phase 2
Olanzapine With or Without Fosaprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)in Patients Receiving Highly Emetogenic Chemotherapy (HEC): A Phase III Randomized, Double Blind, Placebo-Controlled Trial
Olanzapine With or Without Fosaprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)in Patients Receiving Highly Emetogenic Chemotherapy (HEC): A Phase III Randomized, Double Blind, Placebo-Controlled Trial
Enrollment Status: Completed
Publish Date: April 06, 2025
Intervention Type: Other, Drug
Study Phase: Phase 3
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Other
Study Phase: Phase 3
A Phase II Randomized Study of Ramucirumab Plus MK3475 (Pembrolizumab) Versus Standard of Care for Patients Previously Treated With Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)
A Phase II Randomized Study of Ramucirumab Plus MK3475 (Pembrolizumab) Versus Standard of Care for Patients Previously Treated With Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)
Enrollment Status: Completed
Publish Date: September 03, 2024
Intervention Type: Drug, Biological
Study Drugs: Docetaxel, Gemcitabine, Gemcitabine Hydrochloride, Pembrolizumab, Pemetrexed, Pemetrexed Disodium, Ramucirumab
Study Phase: Phase 2
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Enrollment Status: Terminated
Publish Date: April 05, 2023
Intervention Type: Other, Drug
Study Drug: Aspirin
Study Phase: Phase 3
View 8 Less Clinical Trials

1 Total Publications

Molecular Tumor Board Review and Improved Overall Survival in Non-Small-Cell Lung Cancer.
Molecular Tumor Board Review and Improved Overall Survival in Non-Small-Cell Lung Cancer.
Journal: JCO precision oncology
Published: May 14, 2021
Similar Doctors
Advanced in Primary Immunodeficiency (PID)
Dr. Christopher G. Burkeen
Hematology Oncology | Hematology | Oncology
Advanced in Primary Immunodeficiency (PID)
Dr. Christopher G. Burkeen
Hematology Oncology | Hematology | Oncology

Baptist Health Medical Group Inc

521 Robinbrooke Blvd, 
Elizabethtown, KY 
 (0.1 miles away)
270-706-1535
Experience:
9+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Christopher Burkeen is a Hematologist Oncology specialist and a Hematologist in Elizabethtown, Kentucky. Dr. Burkeen has been practicing medicine for over 9 years and is rated as an Advanced provider by MediFind in the treatment of Primary Immunodeficiency (PID). His top areas of expertise are Laryngeal Cancer, Common Variable Immune Deficiency, Primary Immunodeficiency (PID), and Pleuropulmonary Blastoma.

Experienced in Primary Immunodeficiency (PID)
Dr. Corazon A. Veza
Hematology Oncology | Hematology | Oncology
Experienced in Primary Immunodeficiency (PID)
Dr. Corazon A. Veza
Hematology Oncology | Hematology | Oncology
1118 Woodland Dr, 
E Town, KY 
 (1.6 miles away)
270-769-0167
Languages Spoken:
English
See accepted insurances

Corazon Veza is a Hematologist Oncology specialist and a Hematologist in E Town, Kentucky. Dr. Veza is rated as a Distinguished provider by MediFind in the treatment of Primary Immunodeficiency (PID). Her top areas of expertise are Angiosarcoma, Inflammatory Breast Cancer, Paget Disease of the Breast, and Breast Cancer.

Experienced in Primary Immunodeficiency (PID)
Dr. Khuda D. Khan
Hematology Oncology | Hematology | Oncology
Experienced in Primary Immunodeficiency (PID)
Dr. Khuda D. Khan
Hematology Oncology | Hematology | Oncology

Norton Hospitals Inc

315 E Broadway, Fl 4, 
Louisville, KY 
 (37.1 miles away)
502-272-5165
Languages Spoken:
English, Urdu
See accepted insurances
Accepting New Patients

Khuda Khan is a Hematologist Oncology specialist and a Hematologist in Louisville, Kentucky. Dr. Khan is rated as a Distinguished provider by MediFind in the treatment of Primary Immunodeficiency (PID). His top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Small Cell Lung Cancer (SCLC), and Posterior Fossa Tumor. Dr. Khan is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Goodin's expertise for a condition
ConditionClose
    View All 20 Distinguished Conditions
    View All 49 Advanced Conditions
    View All 145 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile